Search research articles
Contact Us
Filters
Showing results (11-20 of 21) with videos related to
Page
of 3
Sort By:
Protein Engineering, Design & Selection : PEDS
|
July 6, 2014
Toward a high-throughput screening platform for directed evolution of enzymes that activate genotoxic prodrugs
J N Copp, E M Williams, M H Rich, et al.
British Journal of Cancer
|
September 1, 1995
Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase
A V Patterson, H Zhang, A Moghaddam, et al.
Nature Medicine
|
May 1, 1997
Targeting gene expression to hypoxic tumor cells
G U Dachs, A V Patterson, J D Firth, et al.
International Journal of Radiation Oncology, Biology, Physics
|
May 15, 1994
The role of DT-diaphorase in determining the sensitivity of human tumor cells to tirapazamine (SR 4233)
A V Patterson, N Robertson, S Houlbrook, et al.
Biochemical Pharmacology
|
February 29, 2000
The relative importance of NADPH: cytochrome c (P450) reductase for determining the sensitivity of human tumour cells to the indolequinone EO9 and related analogues lacking functionality at the C-2 and C-3 positions
M P Saunders, M Jaffar, A V Patterson, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
April 6, 2004
Cytotoxicity of the bioreductive agent RH1 and its lack of interaction with radiation
Joo-Young Kim, C M L West, H Valentine, et al.
Biochemical Pharmacology
|
October 27, 2009
Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954
G A Prosser, J N Copp, S P Syddall, et al.
Biochemical Pharmacology
|
July 17, 2012
Targeted mutagenesis of the Vibrio fischeri flavin reductase FRase I to improve activation of the anticancer prodrug CB1954
P M Swe, J N Copp, L K Green, et al.
Cancer Gene Therapy
|
November 3, 2007
The nitroreductase prodrug SN 28343 enhances the potency of systemically administered armed oncolytic adenovirus ONYX-411(NTR)
D C Singleton, D Li, S Y Bai, et al.
Gene Therapy
|
June 27, 2002
Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours
A V Patterson, K J Williams, R L Cowen, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 21) with videos related to
Sort By:
Page
of 3
Protein Engineering, Design & Selection : PEDS
|
July 6, 2014
Toward a high-throughput screening platform for directed evolution of enzymes that activate genotoxic prodrugs
J N Copp, E M Williams, M H Rich, et al.
British Journal of Cancer
|
September 1, 1995
Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase
A V Patterson, H Zhang, A Moghaddam, et al.
Nature Medicine
|
May 1, 1997
Targeting gene expression to hypoxic tumor cells
G U Dachs, A V Patterson, J D Firth, et al.
International Journal of Radiation Oncology, Biology, Physics
|
May 15, 1994
The role of DT-diaphorase in determining the sensitivity of human tumor cells to tirapazamine (SR 4233)
A V Patterson, N Robertson, S Houlbrook, et al.
Biochemical Pharmacology
|
February 29, 2000
The relative importance of NADPH: cytochrome c (P450) reductase for determining the sensitivity of human tumour cells to the indolequinone EO9 and related analogues lacking functionality at the C-2 and C-3 positions
M P Saunders, M Jaffar, A V Patterson, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
April 6, 2004
Cytotoxicity of the bioreductive agent RH1 and its lack of interaction with radiation
Joo-Young Kim, C M L West, H Valentine, et al.
Biochemical Pharmacology
|
October 27, 2009
Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954
G A Prosser, J N Copp, S P Syddall, et al.
Biochemical Pharmacology
|
July 17, 2012
Targeted mutagenesis of the Vibrio fischeri flavin reductase FRase I to improve activation of the anticancer prodrug CB1954
P M Swe, J N Copp, L K Green, et al.
Cancer Gene Therapy
|
November 3, 2007
The nitroreductase prodrug SN 28343 enhances the potency of systemically administered armed oncolytic adenovirus ONYX-411(NTR)
D C Singleton, D Li, S Y Bai, et al.
Gene Therapy
|
June 27, 2002
Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours
A V Patterson, K J Williams, R L Cowen, et al.
Page
of 3